CTIS2024-511801-51-00进行中（未招募）1 期
SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy of intra-lesional BO-112 in patients with resectable primary low and high risk basal cell carcinoma - BOT-112-204
Highlight Therapeutics S.L.0 个研究点目标入组 60 人开始时间: 2024年4月23日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •Must be = 18 years old, Has primary resectable low or high risk basal cell carcinoma according to the protocol definition, Has diagnostic punch biopsy of all lesions intended for injection available prior to the first dose of BO-112, Has adequate organ function as defined in the protocol, Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of human chorionic gonadotropin [HCG]) within 24 hours prior to the start of study drug, Women of childbearing potential must be willing to use two effective methods of birth control while treated with BO-112 and for 4 weeks after the last treatment. The two forms of birth control authorized are defined as the use of a barrier method of contraception (condom with spermicide) in association with one of the following methods of birth control: bilateral tubal ligation; combined oral contraceptives (estrogens and progesterone) or implanted or injectable contraceptives from the time of informed consent, Male patients with female partners of childbearing potential must be willing to use two adequate contraception methods while treated with BO-112 and for 4 weeks after treatment completion, Capable of giving signed informed consent as described in Appendix 1 which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol, Able and willing to comply with all study requirements, including surgical removal of lesion/lesion site at completion of
排除标准
- •Has any BCC lesion(s) in site of prior radiation or any BCC lesion(s) within 2 cm of the open eyelid margins, Female participants: lactating or pregnant, Has received a live vaccine or mRNA COVID vaccine within 7 days prior to the first dose of study drug or has a vaccination planned during treatment with BO-112 and within 7 days after the last study drug administration, Is immunocompromised, Has any prior systemic anti-lesion therapy or local treatment for study lesions prior to first dose; any chemotherapy or immunotherapy for any other malignancy within 24 months prior to the first dose of BO-112, Has any other concurrent anti-cancer therapy (chemotherapy, immunotherapy, radiotherapy, or any ancillary therapy considered investigational [used for a not approved indication and in the context of a research investigation]) within 28 days of first study drug administration; or plans to participate in an experimental drug study while enrolled in this study., Has any experimental or investigational agents within one month of first BO-112 injection, Has received or is expected to receive treatment with psoralen plus UVA or UVB therapy within 6 months prior to the first dose of BO-112, Requires / or has used topical products within 5 cm of a treatment-targeted BCC lesion or systemic therapies that might interfere with the evaluation of the study medication during the study, Has any medical contraindications to surgery, Has Gorlin’s syndrome, Has clinically active or uncontrolled skin disease or tattoos that would interfere with evaluation of the area surrounding the target lesion, Has another malignant disease requiring treatment, except for adequately treated carcinoma in situ of the breast or of the cervix, low grade prostate cancer on surveillance without any plans for treatment intervention other than hormonal therapy, or prostate cancer that has been adequately treated with prostatectomy or radiotherapy and currently with no evidence of disease or symptoms, Has a history of immunological disorder, severe allergic reaction, moderate or severe asthma or known history of anaphylaxis or any other serious adverse reactions to the investigational products
研究者
相似试验
进行中（未招募）
1 期
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and entospletinib with and without obinutuzumab in subjects with chronic lymphocytic leukemiaAdults with relapsed or refractory chronic lymphocytic leukemiaMedDRA version: 20.1Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2016-002768-15-DEGilead Sciences, Inc.36
进行中（未招募）
1 期
A study evaluating the safety and efficacy of the combination of tirabrutinib (GS-4059) and idelalisib with and without obinutuzumab in subjects with chronic lymphocytic leukemiaAdults with relapsed or refractory chronic lymphocytic leukemia (CLL)MedDRA version: 21.0Level: LLTClassification code 10008976Term: Chronic lymphocytic leukemiaSystem Organ Class: 100000004864EUCTR2015-003909-42-DEGilead Sciences, Inc.36
进行中（未招募）
不适用
A PHASE II, OPEN-LABEL, PROSPECTIVE, MULTICENTER STUDYTO EVALUATE THE EFFICACY AND SAFETY OF SUBSEQUENTTREATMENT WITH THE ZEVALIN (IBRITUMOMAB TIUXETAN)IN ELDERLY ( 60 YEARS) PATIENTS WITH DIFFUSE LARGE BCELLLYMPHOMA AFTER 4 CYCLES OF CHOP21 ?RITUXIMAB(CHOP21-R) THERAPY. - NDDIFFUSE LARGE BCELLLYMPHOMAMedDRA version: 9.1Level: LLTClassification code 10012818Term: Diffuse large B-cell lymphomaEUCTR2006-004851-39-ITAZIENDA OSPEDALIERA DI BOLOGNA POLICLINICO S. ORSOLA M. MALPIGHI
已完成
2 期
A Phase IIb open-label, multi-centre, extension study to explore the long-term safety and efficacy of KH176 in subjects with a genetically confirmed mitochondrial DNA tRNALeu(UUR) m.3243A>G mutation who have completed the KHENERGYZE study KH176-202.mitochondriale aandoeningenMELAS spectrum diseasesmetabolic diseases1002766410029305NL-OMON52925Khondrion B.V.9
进行中（未招募）
1 期
The KHENEREXT study: An open-label long-term extension study to investigate the long-term safety and effectiveness of KH176 in subjects with a mitochondrial DNA mutation.A genetically confirmed mitochondrial desoxyribonucleic acid (DNA) tRNALeu(UUR) m.3243A>G mutation (including but not limited to MELAS. MIDD and mixed phenotypes.MedDRA version: 22.0Level: PTClassification code 10052641Term: Mitochondrial DNA mutationSystem Organ Class: 10010331 - Congenital, familial and genetic disordersEUCTR2020-000832-23-DKKhondrion B.V.27